The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).
 
Drew W. Rasco
Research Funding - Abbvie (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Incyte (Inst); Macrogenics (Inst); Merck (Inst); Seven and Eight Biopharmaceuticals (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Andrea Wang-Gillam
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jacobio; Repugene; Tyme
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); Gossamer Bio (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Verastem (Inst); Xcovery (Inst)
 
Wungki Park
Honoraria - Ipsen
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)
 
Lei Zhou
Consulting or Advisory Role - Exelis; Five Prime Therapeutics; Gossamer Bio
 
Anna Galkin
Employment - Gossamer Bio; Novartis; Okogen (I)
Leadership - Okogen (I)
Stock and Other Ownership Interests - Allergan (I); Biogen (I); Bristol-Myers Squibb (I); Gossamer Bio; Novartis
Patents, Royalties, Other Intellectual Property - Cytorii Therapeutics (I); Novartis
 
Laura L Carter
Employment - Boundless Bio (I); Gossamer Bio; Lycera; Lycera (I)
Stock and Other Ownership Interests - Lycera
Consulting or Advisory Role - Lycera
Expert Testimony - Lycera
 
David Nickle
Employment - Gossamer Bio
 
Jack Li
Employment - Gossamer Bio; Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
 
Beatrice Ferguson
Employment - Celgene; Gossamer Bio; Retrophin
Stock and Other Ownership Interests - Celgene; Gossamer Bio; Retrophin
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Jakob Dupont
Employment - Gossamer Bio; Roche
Leadership - Gossamer Bio; Roche
Stock and Other Ownership Interests - Gossamer Bio; Roche
Patents, Royalties, Other Intellectual Property - Gossamer Bio
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); Gilead Sciences (Inst); Purdue Pharma (Inst); Tanabe Research (Inst)
Research Funding - Aduro Biotech (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); Beigene (Inst); D3 (Inst); Immunomedics (Inst); OncoMed (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)